Ready to join a team committed to moving cutting-edge gene therapies into the clinical setting for patients and families devastated by rare neurological genetic diseases?
AveXis, Inc. is a clinical-stage gene therapy company, dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product currently in development for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality, and for the treatment of SMA Type 2. The U.S. Food and Drug Administration, or FDA, has granted AVXS-101 Orphan Drug Designation for the treatment of all types of SMA and Breakthrough Therapy Designation, as well as Fast Track Designation for the treatment of SMA Type 1. In addition to developing AVXS-101 to treat SMA Type 1 and Type 2, we also plan to develop other novel treatments for rare neurological diseases, including Rett syndrome (RTT) and a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene.
To view our latest job openings and apply, please see below.
Please Note: To 3rd Party Search Firms/Employment Agencies: Please do not call or email any AveXis employee about current/future job openings. All requests should go through Human Resources. All resumes submitted by search firms/employment agencies to any employee at AveXis via-email, the internet or in any form and/or method will be deemed the sole property of AveXis, unless such search firms/employment agencies were engaged under contract by AveXis for an open position. In the event a candidate who was submitted outside of the agency engagement process is hired, no fee or payment of any kind will be paid.